MedTrace Logo

Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial

NCT06121934 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2023-12-29

No results posted yet for this study

Summary

This will be a placebo-controlled, multicenter-randomized prospective study of CPLE (Carica papaya leaf extract) tabs in dengue patients (WHO-Group A, B). The study will enroll 300 eligible dengue cases into two arms: one arm receiving CPLE 1000mg t.i.d for 5 days and the other group receiving a placebo.

The main question to ask is whether CPLE reduces severe disease progression and increases platelet counts in dengue patients.

The participant will be asked to take orally available CPLE capsules at a dose of 1000 mg (2 capsules, 500mg each) or identical placebo three times a day for 5 days

Conditions

  • Dengue

Interventions

DRUG

Carica Papaya Leaf Extract

Active drug: CPLE 500mg 2 capsule t.i.d for 5 dayseive CPLE or placebo once daily for 5 days.

DRUG

Placebo

Placebo: visually matched placebo 2 capsule t.i.d for 5 days

Sponsors & Collaborators

  • Institute of Technology Transfer and Innovation (ITTI)

    collaborator UNKNOWN

  • Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2023-12-20
Completion
2023-12-27

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06121934 on ClinicalTrials.gov